Invention Grant
US09585942B2 Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
有权
胰岛素类似物或其药学上可接受的盐,具有延长治疗效果的药物组合物,胰岛素类似物的用途,治疗糖尿病的剂量方法和方法
- Patent Title: Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
- Patent Title (中): 胰岛素类似物或其药学上可接受的盐,具有延长治疗效果的药物组合物,胰岛素类似物的用途,治疗糖尿病的剂量方法和方法
-
Application No.: US14403513Application Date: 2013-05-22
-
Publication No.: US09585942B2Publication Date: 2017-03-07
- Inventor: Piotr Borowicz , Andrzej Płucienniczak , Jerzy Mikołajczyk , Jarosław Antosik , Jacek Pstrzoch , Justyna Bernat , Diana Mikiewicz-Syguła , Monika Bogiel , Dorota Stadnik , Graźyna Płucienniczak , Boźena Tejchman-Małecka , Tadeusz Głąbski , Iwona Sokołowska , Dariusz Kurzynoga , Anna Wojtowicz-Krawiec , Marcin Zieliński , Malgorzata Kęsik-Brodacka , Natalia Łukasiewicz , Violetta Cecuda-Adamczewska , Monika Pawłowska , Tomasz Pawlukowiec , Jacek Stępniewski
- Applicant: INSTYTUT BIOTECHNOLOGII I ANTYBIOTYKÓW
- Applicant Address: PL Warsaw
- Assignee: Instytut Biotechnologii i Antybiotykow
- Current Assignee: Instytut Biotechnologii i Antybiotykow
- Current Assignee Address: PL Warsaw
- Agency: Cooper & Dunham LLP
- Agent Gary J. Gershik
- Priority: PL399287 20120523
- International Application: PCT/PL2013/000066 WO 20130522
- International Announcement: WO2013/176560 WO 20131128
- Main IPC: A61K38/28
- IPC: A61K38/28 ; C07K5/00 ; C07K7/00 ; C07K16/00 ; C07K17/00 ; C07K14/62 ; A61K38/00

Abstract:
The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called “sawteeth effect”, during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.
Public/Granted literature
Information query
IPC分类: